NCT02791880Completed
Acute Kidney Injury Genomics and Biomarkers in TAVR Study
Genomic and Biomarker Predictors of Acute Kidney Injury and Other Post-Procedural Outcomes Following Transcatheter Aortic Valve Replacement
Source: ClinicalTrials.gov · Last updated 13 Oct 2026
Brief summary (registry, in English)
In the last decade, transcatheter aortic valve replacement (TAVR) has become an increasingly utilized alternative procedure for replacing a stenotic aortic valve. This study collects clinical information, DNA, blood and urine samples (throughout procedural hospitalization) in order to investigate the incidence of acute kidney injury (AKI) in patients undergoing TAVR and to identify key clinical and procedural predictors of AKI. This study seeks to identify blood and urine biomarkers that can be used for early detection of AKI around the time of the procedure. The study seeks to assess for novel genetic variants associated with development of AKI after TAVR. Finally the study seeks to assess for novel genetic variants and biomarkers that are associated with adverse cardiovascular events after TAVR and to further explore how these events may inter-relate with acute kidney injury.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 61 (actual)
- First submitted
- 19 Feb 2016
- Start date
- 25 Oct 2016
- Primary completion date
- 2 Dec 2024
- Lead sponsor
- University of Texas Southwestern Medical Center
- Diseases
- Heart failure, Coronary artery disease, Stroke
- NCT number
- NCT02791880
What you commit to
- Study type: Observational
- Participants enrolled: 61
- From 25 Oct 2016 to the primary completion date, 2 Dec 2024
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- The patient has known hepatitis C that has not been treated with antiviral medications
Other illness
- The patient has known human immunodeficiency virus infection
Age
- The patient is aged less than 18 years.
Other
- The patient cannot or will not provide informed consent.
- The patient's pre-procedural hematocrit is less than 25%.
- In the opinion of the principal investigator, the patient will be unlikely to complete long-term follow up for medical or social reasons (this includes transient patients and patients who have no fixed address).
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Texas Southwestern Medical Center Coordinator of this site? Confirm its status | Dallas | United States | Unknown status |
| William J. Clements University Hospital Coordinator of this site? Confirm its status | Dallas | United States | Unknown status |
| Parkland Health & Hospital Systems Coordinator of this site? Confirm its status | Dallas | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.